Advanced Solid Tumor
Conditions
Brief summary
This is an open label, phase 1 clinical study to evaluate the safety, tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended phase 2 dose (RP2D) of QLS31904 q2w/q3w intravenous use in patients with advanced solid tumors. Additional objectives are to characterise pharmacokinetics and pharmacodynamics, and to evaluate efficacy signals. This study is consisted of phase Ia (Dose Escalation) and phase Ib (Dose Expansion). Phase Ib will further explore QLS31904 in selected patients populations based on data from phase Ia. The Phase Ib objectives, endpoints and design will be specified in a study protocol amendment after availability of phase Ia results.
Interventions
DRUGQLS31904
QLS31904 ONLY
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Understanding and voluntarily signing the informed consent form; 2. Male or female, age≥18 years; 3. Patients with histologically or cytologically confirmed advanced solid tumors including small cell lung cancer, small cell cancers in other organs or neuroendocrine carcinoma who have progression after on theor intolerance to standard of care, or have no effective standard therapeutic regimen; 4. Tumours must be confirmed expression of DLL3. 5. Presence of at least one measurable lesion meeting the requirements in RECIST v1.1 evaluation criteria; 6. ECOG PS score: 0\ 1; 7. Patients with life expectancy ≥3 months; 8. Adequate organ function as defined in protocol. Futher inclusion criteria apply.
Exclusion criteria
1. Having received the treatment targeting CD3 or DLL3 previously; 2. Receiving any systematic antitumor therapy or other investigational product within 4 weeks prior to the first dose of QLS31904; 3. Receiving radiotherapy within 2 weeks prior to the first dose of QLS31904; 4. For the dose-escalation, participants who experienced severe immune-mediated AEs while on treatment with Immune checkpoint inhibitors (e.g., anti PD-L1, anti PD-1, anti CTLA-4) ; 5. Symptomatic central nervous system (CNS) metastasis. 6. History of concurrent serious cerebro- and cardiovascular diseases including but not limited to: unstable angina pectoris, myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months prior to the first doses, poorly controlled hypertension or arrhythmia, or any other arterial thrombosis or embolic event; 7. History of concurrent gastrointestinal diseases including but not limited to: gastrointestinal bleeding or perforation, acute pancreatitis; 8. History of concurrent lung damage including but not limited to: interstitial lung disease, other diseases requiring oxygen inhalation. 9. Presence of active pneumonia or history of noninfectious pneumonia; 10. Active infection requiring systematic treatment/antibiotics or intravenous use of systemic anti-infection therapy with one week prior to the first dose or use for more than 7 days; 11. Known positive for human immunodeficiency virus (HIV); Having evidence on infection of hepatitis C virus (HCV) or syphilis; Hepatitis B virus (HBV) infected individuals with positive HBsAg and HBV DNA copy \>1000 IU/ml or 200 cps/mL; Following treatment according to guidelines, previously HBV infected individuals in screening period can be enrolled only; 12. Presence of active or suspicious autoimmune disease. 13. Previous allogeneic bone marrow transplantation or solid organ transplantation; 14. Major surgery (judged by investigators) or in the recovery period of the surgery within 4 weeks before the first dose of QLS31904. 15. Vaccination of live attenuated vaccine within 4 weeks prior to the first dose of QLS31904; 16. Having other malignant tumor other than the disease investigated within 2 years prior to the ICF; 17. Known allergy to any component of QLS31904; 18. Any other disease or condition of clinical significance that can affect the compliance with the protocol (e.g., history of psychosis or drug abuse), affect the signature of the informed consent form (e.g., drug addiction and drug abuse); 19. Any condition is unsuitable to be involved in this clinical trial, as considered by investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD | Up to 24 approximately months | The maximum tolerated dose (MTD) is defined as the highest dose at which DLT occurs in \<1/3 subjects. The maximum administrated dose (MAD) is defined as the highest dose of all groups if MTD can not be determined. |
| DLT | Up to 28 approximately days | Dose-limiting toxicity (DLT) is defined as any of the specified toxicities evaluated as at least possibly related with the study drug within 28 days after the first dose. |
| RP2D | Up to 24 approximately months | Recommended dose for phase II trials |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of serious adverse event (SAE) | Up to 24 approximately months | Incidence of serious adverse event (SAE) assessed according to NCI-CTCAE 5.0 |
| Severity of serious adverse event (SAE) | Up to 24 approximately months | Severity of serious adverse events (AE) assessed according to NCI-CTCAE 5.0 |
| Incidence of immune related adverse event (irAE) | Up to 24 approximately months | Incidence of immune related adverse event (irAE) assessed according to NCI-CTCAE 5.0 |
| Incidence of clinically significant laboratory examination and abnormal changes in other examinations | Up to 24 approximately months | Incidence of clinically significant laboratory examination and abnormal changes in other examinations assessed according to NCI-CTCAE 5.0 |
| peak concentration (Cmax) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters peak concentration (Cmax); |
| time to peak (Tmax) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters time to peak (Tmax); |
| trough concentration (Ctrough) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters trough concentration (Ctrough) |
| area under the plasma drug concentration-time curve (AUC0-t ) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters area under the plasma drug concentration-time curve (AUC0-t ) |
| area under the plasma drug concentration-time curve (AUC0-inf) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters area under the plasma drug concentration-time curve (AUC0-inf); |
| elimination half-life (t1/2) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters elimination half-life (t1/2) |
| clearance rate (CL) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters clearance rate (CL); |
| mean retention time (MRT) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters mean retention time (MRT) |
| ORR | Up to 24 approximately months | The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria, including objective response rate (ORR). |
| DOR | Up to 24 approximately months | The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria24, including duration of response (DOR); |
| DCR | Up to 24 approximately months | The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria24, including disease control rate (DCR); |
| PFS/PFS6 | Up to 24 approximately months | The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria24, including progression-free survival (PFS) and percents of progression-free survival more than six months; |
| OS | Up to 24 approximately months | The efficacy evaluated by the investigator in accordance with RECIST 1.1 criteria24, including overall survival (OS); |
| ADA | Up to 24 approximately months | incidence of anti-drug body (ADA) |
| Nab | Up to 24 approximately months | concentration of neutralizing antibody (Nab); |
| volume of distribution (Vss) | Up to 24 approximately months | Pharmacokinetic (PK) profile: drug concentration in individual subject at different time points after administration; pharmacokinetic parameters volume of distribution (Vss) |
| Incidence of adverse event (AE) | Up to 24 approximately months | Incidence of adverse events (AE) assessed according to NCI-CTCAE 5.0 Incidence of adverse events (AE) assessed according to NCI-CTCAE 5.0 |
| Severity of adverse event (AE) | Up to 24 approximately months | Severity of adverse events (AE) assessed according to NCI-CTCAE 5.0 |
Other
| Measure | Time frame | Description |
|---|---|---|
| DLL3 expression in tumor tissue | Up to 24 approximately months | To explore the correlation between DLL3 expression in tumor tissue and the efficacy |
| Objective response based on iRECIST criteria in patients with measurable disease | Up to 24 approximately months | Objective response based on immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria in patients with measurable disease |
Countries
China
Contacts
Primary ContactHuayuan Wang
Outcome results
None listed